Home
About
FAQ
History (3)
IMP-3 is a novel progression marker in malignant melanoma.
Principal Investigator
Visual Acuity Outcomes in Diabetic Macular Edema With Fluocinolone Acetonide 0.2 µg/Day Versus Ranibizumab Plus Deferred Laser (DRCR Protocol I).
See All 3 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Principal Investigator
Overview
researcher role of
Weaver, Kathryn
contributes to
Cancer-Related Follow-Up Care Experiences of Rural Cancer Survivors